Klebsiella Pneumoniae Infections - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 36

Klebsiella Pneumoniae Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Klebsiella Pneumoniae Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections. Klebsiella Pneumoniae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Klebsiella Pneumoniae Infections.
- A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Klebsiella Pneumoniae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Klebsiella Pneumoniae Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Klebsiella Pneumoniae Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Klebsiella Pneumoniae Infections 7
Klebsiella Pneumoniae Infections Therapeutics under Development by Companies 9
Early Clinical Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Klebsiella Pneumoniae Infections Therapeutics – Products under Development by Companies 12
Companies Involved in Klebsiella Pneumoniae Infections Therapeutics Development 13
AlphaRx, Inc. 13
Rib-X Pharmaceuticals, Inc. 14
Orchid Chemicals & Pharmaceuticals Ltd 15
Achaogen Inc. 16
Phico Therapeutics Ltd. 17
Cantab Biopharmaceuticals Limited 18
Klebsiella Pneumoniae Infections – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
plazomicin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ciprofloxacin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RX-04 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
SASPject PT3.X - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
OCID5090 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Gram-Negative Programme - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Snare Antibacterial For Gram Negative Infections - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Klebsiella Pneumoniae Infections Therapeutics – Drug Profile Updates 32
Klebsiella Pneumoniae Infections Therapeutics - Dormant Products 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Number of Products Under Development for Klebsiella Pneumoniae Infections, H2 2012 7
Products under Development for Klebsiella Pneumoniae Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Early Clinical Stage Development, H2 2012 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
AlphaRx, Inc., H2 2012 13
Rib-X Pharmaceuticals, Inc., H2 2012 14
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012 15
Achaogen Inc., H2 2012 16
Phico Therapeutics Ltd., H2 2012 17
Cantab Biopharmaceuticals Limited, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Klebsiella Pneumoniae Infections Therapeutics – Drug Profile Updates 32
Klebsiella Pneumoniae Infections Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Klebsiella Pneumoniae Infections, H2 2012 7
Products under Development for Klebsiella Pneumoniae Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Early Clinical Stage Products, H2 2012 10
Discovery and Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Customers who bought this item also bought

• Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance
• Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance
• Streptococcal Infections - Pipeline Review, H2 2012
• Fungal Infections - Pipeline Review, H2 2012
• Mycobacterium Infections - Pipeline Review, H2 2012
• Other Viral Infections - Pipeline Review, H2 2012
• Influenza A Infections - Pipeline Review, H2 2012
• Urinary Tract Infections - Pipeline Review, H2 2012
• Rotavirus Infections - Pipeline Review, H2 2012
• Bacterial Respiratory Tract Infections - Pipeline Review, H2 2012